Development and Validation of Different Chromatographic Methods for Analysis of Cabergoline in the Presence of Its Degradation Products: Studying Degradation Profile
- 34 Downloads
Cabergoline is widely used as a prolactin secretion inhibitor and as a treatment for Parkinson’s disease. Studying the structure of cabergoline, it contains a urea moiety and an amide group which are sensitive to degradation by hydrolysis as well as an alkene bond that is susceptible to oxidation. Degradation was performed regarding ICH recommendations including hydrolysis (pH from 1.3 to 12.7 using HCl or NaOH with different molarities), oxidation, photo, and thermal degradations. The drug was highly sensitive to all studied conditions except thermal degradation with the production of three major degradation products which were isolated and identified using IR and MS analyses. Two stability indicating chromatographic methods were developed for quantification of the drug in the presence of its degradation products. The first method was HPTLC which depended on using a developing system of butanol:methanol:triethyl amine (95:5:10, by volume) and UV scanning at 280 nm. The second method was HPLC at which the drug and degradation products were separated within 5 min using acetonitrile: 0.05% aqueous triethylamine (TEA) (pH adjusted to 6.5 using 1% aqueous H3PO4) [70:30, v/v] and UV scanning was performed at 225 nm. Validation parameters were calculated according to ICH recommendations and all parameters were within the acceptable limits. Comparison was made between the developed methods and the previously published ones; the developed methods were found to be superior regarding analysis time, studying different degradation pathways, and identifying the degradation products.
KeywordsHPTLC HPLC IR MS Cabergoline Degradation pathway
The authors express their appreciation and would like to thank Dr. Asmaa Mohamed Aboul Magd, Pharmaceutical Chemistry Department, Nahda University (NUB), Beni-Suef, Egypt, for his effort in elucidation of the chemical structure of the degradation products.
Both Dr. NFF and Dr. NSA did the practical work and wrote the manuscript.
This work is not funded.
Compliance with Ethical Standards
Conflict of interest
Nehal Fayek Farid declares that she has no conflict of interest. Nada Sayed Abdelwahab declares that she has no conflict of interest.
Research involving human participants and/or animals
No human volunteers or animals were used in this work.
Ethics approval and consent to participate
Consent for publication
- 1.British Pharmacopoeia (2012) Her Majesty’s stationary office. Electronic Version, LondonGoogle Scholar
- 2.The United States Pharmacopeia (2012) National formulary 35, 30th edn. United States Pharmacopeia Convention Inc., New YorkGoogle Scholar
- 3.Budavari S (2006) The Merck index, 14th edn. Merck and Co Inc., Whitehouse StationGoogle Scholar
- 4.Martindale-Extra Pharmacopoeia (2005) The complete drug references, 34th edn. The pharmaceutical Press, LondonGoogle Scholar
- 5.Salman D, Dogan A, Basci NE (2011) Spectrophotometric analysis of cabergoline in pharmaceutical preparations. Latin Am J Pharm 30:304–310Google Scholar
- 7.Rambabu C, Jyothirmayee CA, Raju KN (2012) Spectrophotometric determination of cabergoline in tablet dosage forms. Int J Pharm Chem Biolog Sci (IJPCBS) 2(1):72–77Google Scholar
- 8.Rambabu C, Jyothirmayee CA, Raju KN (2012) Spectrophotometric determination of cabergoline in tablet dosage forms. Asian J Res Chem 5(2):279–281Google Scholar
- 9.Rambabu C, Jyothirmayee CA, Raju KN (2012) Spectrophotometric determination of cabergoline in tablet dosage form. Int J Pharm Chem Biol Sci 2(1):72–77Google Scholar
- 10.Jyothirmayee CA, Raju KN (2014) RP-HPLC method for the estimation of cabergoline in pharmaceutical formulations. Int J Res Pharm Chem 4(4):977–981Google Scholar
- 13.Lasan VM, Indrekar TD (2016) Development and validation of stability indicating analytical method for the determination of cabergoline. Int J Pharm Res Sch (IJPRS) 5(1–2):141–150Google Scholar
- 17.Abiramasundair A, Joshi RP, Jalani HB, Sharma JA, Pandya DH, Pandya AN, Sudarsanam V, Vasu KK (2014) Stability-indicating assay method for determination of actarit, its process related impurities and degradation products: insight into stability profile and degradation pathways. J Pharm Anal 4:374–383CrossRefGoogle Scholar
- 20.Sabry SM, Belal TS, Barary MH, Ibrahim MEA (2013) A validated HPLC method for the simultaneous determination of naftidrofuryl oxalate and its degradation product (metabolite), naftidrofuryl acid: applications to pharmaceutical tablets and biological samples. Drug Test Anal 5:500–508CrossRefGoogle Scholar
- 23.ICH, Harmonized Tripartite Guidelines (2003) Stability testing of new drug substances and products. Q1A (R2): International conference on harmonization, IFPMA, Geneva, pp 1–18Google Scholar
- 24.Through website: http://www.toxipedia.org/display/toxipedia/Chloroform. Accessed 29 Dec 2018
- 25.Through website: https://owlcation.com/stem/Chloroform-in-the-Environment-and-its-Dangers. Accessed 29 Dec 2018
- 32.International Conference on Harmonisation (ICH) (2005) Validation of analytical procedures: text and methodology Q2(R1). ICH, pp 1–13Google Scholar